Velofix(tm) Interbody Fusion System

K171749 · U&I Corporation · ODP · Jul 13, 2017 · Orthopedic

Device Facts

• Record ID: K171749
• Device Name: Velofix(tm) Interbody Fusion System
• Applicant: U&I Corporation
• Product Code: ODP · Orthopedic
• Decision Date: Jul 13, 2017
• Decision: SESE
• Submission Type: Traditional
• Regulation: 21 CFR 888.3080
• Device Class: Class 2
• Attributes: Therapeutic

Intended Use

The Velofix100 PEEK Cervical Cage is indicated for intervertebral body fusion in skeletally mature patients with degenerative disc disease (DDD) of the cervical spine with accompanying radicular symptoms at one disc level from the C2-C3 disc to the C7-T1 disc. DDD is defined as discogenic pain with degeneration of the disc confirmed by history and radiographic studies. The device system is designed for use with supplemental fixation and with autograft to facilitate fusion. Patients should have at least six weeks of non-operative treatment prior to treatment with an intervertebral cage. The Velofix ™ PEEK Lumbar Cage is indicated for use with autogenous bone graft in patients with degenerative disc disease(DDD) at one or two levels for L2 to S1. These DDD patients may also have up to Grade 1 Spondylolisthesis or retrolisthesis at the involved levels. DDD is defined as back pain of discongenic origin with degeneration of the disc confirmed by history and radiographic studies. These patients should be skeletally mature and have had six months of non-operative treatment. These devices are intended to be used with supplemental fixation.

Device Story

Interbody fusion system consisting of PEEK-OPTIMA cervical and lumbar cages; used to facilitate spinal fusion in conjunction with autograft and supplemental fixation. Implants feature open architecture for bone graft packing and tantalum markers for radiographic visualization. Cervical cages implanted via anterior approach; lumbar cages via posterior (PLIF) or transforaminal (TLIF) approaches. Used by surgeons in clinical settings to treat degenerative disc disease. Device provides structural support to intervertebral space, promoting fusion and alleviating discogenic pain.

Clinical Evidence

Bench testing only. Performance evaluated using Finite Element Analysis (FEA) for static compression and static torsion according to ASTM F2077. No clinical data provided.

Technological Characteristics

Materials: PEEK-OPTIMA LT 1 (ASTM F2026) body, tantalum markers (ASTM F560). Instruments: stainless steel (ASTM F899). Design: open architecture cage with varying heights, widths, and angles. Energy source: none (mechanical). Connectivity: none.

Indications for Use

Indicated for skeletally mature patients with degenerative disc disease (DDD) of the cervical spine (C2-T1, one level) with radicular symptoms, or lumbar spine (L2-S1, one or two levels) with or without Grade 1 Spondylolisthesis/retrolisthesis. Requires six weeks (cervical) or six months (lumbar) of failed non-operative treatment.

Regulatory Classification

Identification

An intervertebral body fusion device is an implanted single or multiple component spinal device made from a variety of materials, including titanium and polymers. The device is inserted into the intervertebral body space of the cervical or lumbosacral spine, and is intended for intervertebral body fusion.

Special Controls

*Classification.* (1) Class II (special controls) for intervertebral body fusion devices that contain bone grafting material. The special control is the FDA guidance document entitled “Class II Special Controls Guidance Document: Intervertebral Body Fusion Device.” See § 888.1(e) for the availability of this guidance document.(2) Class III (premarket approval) for intervertebral body fusion devices that include any therapeutic biologic (e.g., bone morphogenic protein). Intervertebral body fusion devices that contain any therapeutic biologic require premarket approval. (c) *Date premarket approval application (PMA) or notice of product development protocol (PDP) is required.* Devices described in paragraph (b)(2) of this section shall have an approved PMA or a declared completed PDP in effect before being placed in commercial distribution.

Predicate Devices

• Velofix™ Interbody Fusion System (K132926)
• Velofix™ Interbody Fusion System (K140864)

Submission Summary (Full Text)

{0}------------------------------------------------

Food and Drug Administration 10903 New Hampshire Avenue Document Control Center - WO66-G609 Silver Spring, MD 20993-0002

DEPARTMENT OF HEALTH & HUMAN SERVICES · USA

July 13, 2017

U&I Corporation Ms. Jee Ae Bang Regulatory Affairs 20. Sandan-ro 76beon-gil(Rd) Uijeongbu-si. Gyeonggi-do Korea 11781

Re: K171749

Trade/Device Name: Velofix™ Interbody Fusion System Regulation Number: 21 CFR 888.3080 Regulation Name: Intervertebral Body Fusion Device Regulatory Class: Class II Product Code: ODP Dated: June 9, 2017 Received: June 13, 2017

Dear Ms. Bang:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR

{1}------------------------------------------------

Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical devicerelated adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Division of Industry and Consumer Education at its toll-free number [phone] or [phone] or at its Internet address

http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to

http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Industry and Consumer Education at its toll-free number [phone] or [phone] or at its Internet address

http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.

Sincerely.

Mark N. Melkerson -S

Mark N. Melkerson Director Division of Orthopedic Devices Office of Device Evaluation Center for Devices and Radiological Health

Enclosure

{2}------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration

## Indications for Use

# 510(k) Number (if known)

K171749

Device Name VelofixTM Interbody Fusion System

#### Indications for Use (Describe)

The VelofixTM PEEK Cervical Cage is indicated for intervertebral body fusion in skeletally mature patients with degenerative disc disease (DDD) of the cervical spine with accompanying radicular symptoms at one disc level from the C2-C3 disc to the C7-T1 disc. DDD is defined as discogenic pain with degeneration of the disc confirmed by history and radiographic studies. The device system is designed for use with supplemental fixation and with autograft to facilitate fusion. Patients should have at least six weeks of non-operative treatment with an intervertebral cage.

The VelofixTM PEEK Lumbar Cage is indicated for use with autogenous bone graft in patients with degenerative disc disease(DDD) at one or two levels for L2 to S1. These DDD patients may also have up to Grade 1 Spondylolisthesis or retrolisthesis at the involved levels. DDD is defined as back pain of discongenic origin with degeneration of the disc confirmed by history and radiographic studies. These patients should be skeletally mature and have had six months of non-operative treatment. These devices are intended to be used with supplemental fixation.

| Type of Use (Select one or both, as applicable) | Prescription Use (Part 21 CFR 801 Subpart D) Over-The-Counter Use (21 CFR 801 Subpart C) |
|-------------------------------------------------|--------------------------------------------------------------------------------------------|
|-------------------------------------------------|--------------------------------------------------------------------------------------------|

CONTINUE ON A SEPARATE PAGE IF NEEDED.

This section applies only to requirements of the Paperwork Reduction Act of 1995.

***DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.***

The burden time for this collection of information is estimated to average 79 hours per response, including the
time to review instructions, search existing data sources, gather and maintain the data needed and complete
and review the collection of information. Send comments regarding this burden estimate or any other aspect
of this information collection, including suggestions for reducing this burden, to:

Department of Health and Human Services
Food and Drug Administration
Office of Chief Information Officer
Paperwork Reduction Act (PRA) Staff
[[e-mail]](mailto:[e-mail])

"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of
information unless it displays a currently valid OMB number."

Form Approved: OMB No. 0910-0120 Expiration Date: January 31, 2017 See PRA Statement below.

{3}------------------------------------------------

# 510(k) Summary

| Manufacturer: | U & I Corporation<br>20, Sandan-ro 76beon-gil(Rd), Uijeongbu-si, Gyeonggi-do,<br>Korea, 11781 |
|------------------------------|-----------------------------------------------------------------------------------------------|
| Sponsor: | U & I Corporation<br>20, Sandan-ro 76beon-gil(Rd), Uijeongbu-si, Gyeonggi-do,<br>Korea, 11781 |
| Sponsor Contact: | Jee Ae Bang, Regulatory Affairs<br>[phone]<br>[e-mail] |
| Date Prepared: | June 09, 2017 |
| Device Name: | Trade Name: Velofix™ Interbody Fusion System |
| Classification Name: | Spinal Intervertebral Body Fusion Device, Cervical<br>, per 21 CFR 888.3080 |
| Common Name: | Intervertebral Body Fusion Device, IBF Device |
| Product Code: | ODP |
| Predicate Devices (Primary): | Velofix™ Interbody Fusion System (K132926, K140864) |

## Description of Device:

The Velofix™ Interbody Fusion System(K132926) consists of implants available in various heights, width and angle with an open architecture to accept packing of autogenous bone graft and consist of:

- 1) Cervical Interbody Fusion Device (Velofix™ PEEK Cervical Cage), which may be implanted as a single device via an anterior approach.
- 2) Lumbar Interbody Fusion Device (Velofix™ PEEK Lumbar Cage), which may be implanted.
- o Bilaterally via a posterior(PLIF) approach;
- o As a single device via a transforaminal(TLIF) approach;

The Velofix™ Interbody Fusion System contains additional surface and angle in PEEK Cervical cages of the Velofix™ Interbody Fusion System (Cleared: K132926, K140864).

{4}------------------------------------------------

Image /page/4/Figure/1 description: The image is a diagram of the Velofix Interbody Fusion System. The system includes the Velofix PEEK Cervical Cage (K132926, K140864), the Velofix PEEK Lumbar Cage (K132926, K140864), and the Velofix PEEK Cervical Convex Cage (Pending). The Velofix Interbody Fusion System is listed as (K132926, K140864).

Figure 1. A diagram of Velofix™ Interbody Fusion System

The implants are made of radiolucent polymer polyether-ether-ketone(PEEK-OPTIMA LT 1, ASTM F2026) body with the x-ray markers made of tantalum markers (ASTM F560). The Velofix™ PEEK Cervical Cage is implanted by using the instruments manufactured from stainless steel materials that conform to ASTM F899.

## Intended Use:

The Velofix100 PEEK Cervical Cage is indicated for intervertebral body fusion in skeletally mature patients with degenerative disc disease (DDD) of the cervical spine with accompanying radicular symptoms at one disc level from the C2-C3 disc to the C7-T1 disc. DDD is defined as discogenic pain with degeneration of the disc confirmed by history and radiographic studies. The device system is designed for use with supplemental fixation and with autograft to facilitate fusion. Patients should have at least six weeks of non-operative treatment prior to treatment with an intervertebral cage.

The Velofix ™ PEEK Lumbar Cage is indicated for use with autogenous bone graft in patients with degenerative disc disease(DDD) at one or two levels for L2 to S1. These DDD patients may also have up to Grade 1 Spondylolisthesis or retrolisthesis at the involved levels. DDD is defined as back pain of discongenic origin with degeneration of the disc confirmed by history and radiographic studies. These patients should be skeletally mature and have had six months of non-operative treatment. These devices are intended to be used with supplemental fixation.

{5}------------------------------------------------

## Substantial Equivalence:

The additional surface and angle of Velofix™ Interbody Fusion System is substantially equivalent to Velofix™ Interbody Fusion System(Cleared:K132926) in design, material, mechanical performance, function and intended use.

The mechanical performance of the additional surface and angle of Velofix'™ Interbody Fusion System met the acceptance criteria which have been established from the predicate device.

#### 1. Comparison Technological Characteristics

The predicate and proposed devices have the similar intended use and basic fundamental scientific technology and share the following similarities;

- The same indications for use O
- Similar design features O
- The same materials
- The equivalent mechanical performance

## 2. Performance

The additional surface and angle of Velofix™ Interbody Fusion System was evaluated using FEA method to assess that no new safety and efficiency issues were raised with this new type of device. The evaluation met all acceptance criteria and verifies that performance of the additional surface and angle of Velofix" Interbody Fusion System is substantially equivalent to predicate device.

The following Finite Element Analysis (FEA) was performed:

- (1) Static compression evaluation according to ASTM F2077
- (2) Static torsion evaluation according to ASTM F2077

## 3. Conclusion

The data and information provided in this submission support the conclusion that the Velofix' " PEEK Cervical Convex Cage is substantially equivalent to predicate device with respect to indications for use and technological characteristics.